Search
BCL-005
go.drugbank.com/drugs/DB17242ExperimentalBCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells.
Stavudine
go.drugbank.com/drugs/DB00649ApprovedInvestigationalA dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Maropitant
go.drugbank.com/drugs/DB11427ExperimentalVet approvedIt was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.
rhIGFBP-3
go.drugbank.com/drugs/DB05897InvestigationalIt is developed by Insmed and is currently under phase I of the clinical trial.
Golotimod
go.drugbank.com/drugs/DB05475InvestigationalIt has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses, and enhance IL-2 and INF-g production. … Due to this preferential activation of Th1 cytokine production, SCV-07 may show utility in treatment of tuberculosis. It can be administered orally or subcutaneously.
Lubazodone
go.drugbank.com/drugs/DB09196ExperimentalLubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was
LGD2941
go.drugbank.com/drugs/DB05234ExperimentalLGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
KF-0210
go.drugbank.com/drugs/DB17476InvestigationalKF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.
TDI-01
go.drugbank.com/drugs/DB19450InvestigationalTDI-01 is a small molecule is being developed by Beijing Tide Pharmaceutical.
Plasmin (Human)
go.drugbank.com/drugs/DB22676InvestigationalThe enzyme plasmin causes clot lysis by cleaving fibrin, a clot component.[L53453]